Equity
€129,921 ▲ 71.9%
Equity rose in 2025 from €75,585 to €129,921.
PHARMEDIC
Lifetime
7 annual accounts with figures on one time axispeak €223,924 (2025)
€223,924▲ 37.9%
peak €54,336 (2025)
€54,336▲ 189%
peak €129,921 (2025)
€129,921▲ 71.9%
€1.2m▼ 4.8%
peak 2.1 FTE (2020)
-not published
Board4 names since 2018
2 directorsDamienne HALLEUX and 1 other
Documentsfilings and deeds
26-08-202626 days late
2025micro format
Gross margin from €162,418 to €223,924Result from €18,777 to €54,336Equity from €75,585 to €129,921Cash from €100,486 to €57,121
Key points
from the 2025 annual accountsTurnover
≈ €560,000 estimated
The micro format states no turnover.
Debts
€1.2m 90% of the balance sheet
Financial debts 70%Suppliers 4%Taxes and wages 1%Other 25%
Of this, €351,768 falls due within a year.
Filings
7 annual accounts 7 late
The 2023 accounts came latest: 61 days after the end of the period.
Starting capital
€18,600 100 shares
Position in the sector
10.1%
Lower solvency than 84% of companies in fabricated metal products. Sector median 44.2% · 2,343 companies.
Checked score
64
Healthy
Financially stronger than 42% of micro companies in fabricated metal products (NACE 25)
Probability in this band: 0.55% to 1.5%
Bankruptcy probability within 12 months
1.4% Low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.5% across 3,709 companies (NACE 25, micro).
About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
12-2024: 2.9%
01-2025: 2.9%● unchanged vs 12-2024
02-2025: 3.0%▲ +0.1 percentage points vs 01-2025
03-2025: 2.5%▼ -0.5 percentage points vs 02-2025
04-2025: 2.8%▲ +0.3 percentage points vs 03-2025
05-2025: 3.3%▲ +0.5 percentage points vs 04-2025
06-2025: 3.6%▲ +0.3 percentage points vs 05-2025
07-2025: 3.8%▲ +0.2 percentage points vs 06-2025
08-2025: 2.6%▼ -1.2 percentage points vs 07-2025
09-2025: 2.8%▲ +0.2 percentage points vs 08-2025
10-2025: 4.1%▲ +1.3 percentage points vs 09-2025highest value
11-2025: 1.7%▼ -2.4 percentage points vs 10-2025
12-2025: 1.7%● unchanged vs 11-2025
01-2026: 1.7%● unchanged vs 12-2025
02-2026: 1.7%● unchanged vs 01-2026
03-2026: 1.8%▲ +0.1 percentage points vs 02-2026
04-2026: 1.8%● unchanged vs 03-2026
05-2026: 1.9%▲ +0.1 percentage points vs 04-2026
06-2026: 2.1%▲ +0.2 percentage points vs 05-2026
07-2026: 2.2%▲ +0.1 percentage points vs 06-2026
08-2026: 2.7%▲ +0.5 percentage points vs 07-2026
09-2026: 1.4%▼ -1.3 percentage points vs 08-2026lowest value
10-2026: 1.4%● unchanged vs 09-2026lowest value
11-2026: 1.4%● unchanged vs 10-2026lowest value
Financial strengthAverage
Score breakdown
raises risk
Last filed accounts filed 26 days late; 2 of the last 3 accounts late
Equity €129,921 (10.1% of total assets)
Sector: Manufacture of fabricated metal products, except machinery and equipment (NACE 25)
lowers risk
Size: total assets €1.3m
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 25, micro). It does better than 14% of them on solvency, 34% on liquidity, 29% on profitability and 90% on growth.
The bankruptcy probability was computed on 10-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the low class on 30-06-2025, 0.8% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,274 companies had the same profile as PHARMEDIC has now. Each dot stands for 9 companies, two years later.
94.7%
were still trading
2.5%
stopped another way
2.5%
went bankrupt
Another 0.2% stopped without a precise date, possibly only after those two years.
That fits the bankruptcy probability of PHARMEDIC itself: 1.4% within 12 months.
Test of the method
The method was tested on the 497,448 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,274 companies, not a prediction for PHARMEDIC. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €8,000 on 30-day terms is acceptable
Liquidity is tight, with a current ratio of 1.01 (0.94 in 2024), below the usual 1.5. Short-term debt is 27.4% and cash 4.4% of total assets. 89.9% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises risk
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 2343 sector peers (2025).
NBB · sector comparisonPosition among 2343 sector peers
Solvency
better than 16%
← weakest
strongest →
raises risk · 2025 accounts filed 26 days late
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 26-08-2026, 26 days later. Nearly half (47%) of Belgian companies file late; of those that file 1 to 90 days late, 2.0% are now bankrupt, dissolved or in another special legal status, against 1.66% of all filers. A delay like this does not count in the score.
NBB · 7 filingsDeviation from the deadline
2025
26 days late
2024
60 days late
2023
61 days late
2022
31 days late
2021
31 days late
2020
30 days late
2019
31 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 7 accounts on average 39 days after the deadline. In the sector (NACE 25), the median for financial year 2024 was 7 days before the deadline, and 35% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 31 August (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven monthsWhere today falls in the filing period
11-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
- JADIN Jean-François Henri Marie-Rose 50 sharesdeed of 13-12-2018
- HALLEUX Damienne Anne Emmanuelle Ghislaine 50 sharesdeed of 13-12-2018
Recent changes
Registered in the Peppol Directory
Reachable for e-invoices through 0208:0715682133
Company renamed from STEEL & MORE to PHARMEDIC
Registered office moved from Hemptinne to Courrière · New registered office: Rue du Fays, numéro 1, 5336 Courrière · Previous registered office: Rue des Cortys 12, 5380 Hemptinne (Fernelmont) · General meeting of 28-06-2023 · Gazette deed
New establishment in Assesse
Pharma Courrière, Rue du Fays 1
Changes of role: Damienne HALLEUX (director) and Jean-François JADIN (director)
“La ferronnerie; La construction métallique; L’ébénisterie; La fabrication et la pose de menuiseries…” (deed in French) · Director discharge: Damienne HALLEUX · Director discharge: Jean-François JADIN · General meeting of 16-02-2023 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| PHARMEDIC Assesse | €1.3m | €223,924 | 10.1% | - |
| Smederij Van de Velde Geert Berlare | €1.0m | €249,157 | 30.5% | - |
| WAUTEAM Fleurus | €1.6m | €310,698 | 4.6% | - |
| GEURTS CORP. Bassenge | €1.0m | €172,667 | 18.1% | - |
| SMEDERIJ DE BRUYN Aalst | €0.9m | €262,142 | 12.0% | - |
| MY STEEL Malmedy | €0.8m | €281,516 | 19.2% | 3.3 |
| VDH Constructie Stekene | €1.2m | €452,953 | 35.9% | - |
These companies have the same main activity as PHARMEDIC: forging of metal (NACE 25401). They are comparable in size and age: total assets between €756,000 and €1.6m, founded between 2015 and 2021.
Official details
Source: KBO- Status
- Active since 11-12-2018Normal situation
- Activity
- Forging of metalNACE 25401and 1 other
- Establishment units
- 2.282.785.0335081 La Bruyère, since 11-12-2018
- 2.339.827.8625380 Fernelmont, since 01-12-2022and 1 other
- Financial year end
- 31 December
- Peppol
- Reachable since 18-01-2026
Insights on PHARMEDIC
PHARMEDIC files the micro format. That format states no turnover. The gross margin rose from €118,903 in 2019 to €223,924 in 2025.
The balance sheet grew most from 2021 to 2023 through fixed assets, financed with long-term debt.
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about PHARMEDIC
- What is the company number of PHARMEDIC?
- The company number of PHARMEDIC is 0715.682.133. The VAT number is the same number with BE in front: BE 0715.682.133.
- Where is PHARMEDIC based?
- The registered office is at Rue du Fays 1, 5336 Assesse.Company details
- What does PHARMEDIC do?
- According to the KBO register, the main activity is forging of metal (NACE 25401).
- What is the legal form of PHARMEDIC?
- PHARMEDIC is a private limited company (BV).
- When was PHARMEDIC founded?
- PHARMEDIC was founded on 11-12-2018.
- Is PHARMEDIC still active?
- Yes, PHARMEDIC is an active enterprise in the KBO register.
- How many employees does PHARMEDIC have?
- PHARMEDIC had an average of 0.9 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of PHARMEDIC?
- The turnover in financial year 2025 is ≈ €560,000. This figure is estimated from the gross margin of €223,924 and 2,203 comparable companies of the same size. It probably lies between €370,000 and €870,000. It is a rough estimate.
- Is PHARMEDIC profitable?
- In financial year 2025, PHARMEDIC made a profit of €54,336.
- Where can I find the annual accounts of PHARMEDIC?
- PHARMEDIC filed 7 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of PHARMEDIC due?
- PHARMEDIC must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.